Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 April 2010Website:
http://www.vbivaccines.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 22:04:50 GMTDividend
Analysts recommendations
Institutional Ownership
VBIV Latest News
VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.
VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered directing offering for shares of VBIV stock.
VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.
What type of business is VBI Vaccines?
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
What sector is VBI Vaccines in?
VBI Vaccines is in the Healthcare sector
What industry is VBI Vaccines in?
VBI Vaccines is in the Biotechnology industry
What country is VBI Vaccines from?
VBI Vaccines is headquartered in United States
When did VBI Vaccines go public?
VBI Vaccines initial public offering (IPO) was on 26 April 2010
What is VBI Vaccines website?
https://www.vbivaccines.com
Is VBI Vaccines in the S&P 500?
No, VBI Vaccines is not included in the S&P 500 index
Is VBI Vaccines in the NASDAQ 100?
No, VBI Vaccines is not included in the NASDAQ 100 index
Is VBI Vaccines in the Dow Jones?
No, VBI Vaccines is not included in the Dow Jones index
When does VBI Vaccines report earnings?
The next expected earnings date for VBI Vaccines is 14 August 2024